PE27799A1 - FORMULATIONS AND POLYMORPHIC FORMS OF DESPHERRIOXAMINE AND ITS PREPARATION - Google Patents

FORMULATIONS AND POLYMORPHIC FORMS OF DESPHERRIOXAMINE AND ITS PREPARATION

Info

Publication number
PE27799A1
PE27799A1 PE1997001097A PE00109797A PE27799A1 PE 27799 A1 PE27799 A1 PE 27799A1 PE 1997001097 A PE1997001097 A PE 1997001097A PE 00109797 A PE00109797 A PE 00109797A PE 27799 A1 PE27799 A1 PE 27799A1
Authority
PE
Peru
Prior art keywords
despherrioxamine
refers
salt
acid
crystal
Prior art date
Application number
PE1997001097A
Other languages
Spanish (es)
Inventor
Nicholas Lowther
Joanne Nicklin
Alan Steward
Peter Hoogevest
Andre Joseph Geoffroy
Hans Hirt
Andreas Burkhard
Ian Francis Hassan
Erwin Marti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9625878.5A external-priority patent/GB9625878D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE27799A1 publication Critical patent/PE27799A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA FORMULACION PARENTERAL DE LIBERACION SOSTENIDA, QUE COMPRENDE: PARTICULAS DE 5� A 10� DE UNA SAL DE DESFERRIOXAMINA-B DE UN ACIDO SULFONICO ALIFATICO DE AL MENOS 8 CARBONOS, SUSPENDIDA EN ACEITE. TAMBIEN SE REFIERE A UNA FORMA CRISTALINA DE 1-DECANSULFONATO DE DESFERRIOXAMINA DE FORMULA (I), CARACTERIZADO POR UN PUNTO DE FUSION DE 154�C A 158�C, Y POR UN PATRON DE DIFRACCION DE RAYOS X EN 2U�: 3,1 4,2 7,3 8,4 9,4 10,5 13,7 16,8 17,4 18,0 18,4 19,6 20,1 20,9 22,3 23,7 25,1 25,6. TAMBIEN SE REFIERE AL PROCEDIMIENTO DE PREPARACION DE DICHO CRISTAL, QUE COMPRENDE: CALENTAR UNA SOLUCION DE METANOSULFONATO DE DESFERRIOXAMINA; AGREGAR UNA CANTIDAD EQUIMOLAR DE UNA SAL DE ACIDO 1-DECANSULFONICO; INDUCIR LA CRISTALIZACION CON UN CRISTAL DE SIEMBRA Y CONTINUAR AGREGANDO EL RESTO DE LA CANTIDAD EQUIMOLAR DE LA SAL DE ACIDO 1-DECANSULFONICO, OBTENIENDOSE UNA SOLUCION SATURADA EN CALIENTE DE 1-DECANSULFONATO DE DESFERRIOXAMINA EN UN SOLVENTE POLAR, A UNA TEMPERATURA ELEVADA; LA CRISTALIZACION OCURRE A UNA VELOCIDAD DE ENFRIAMIENTO DE 1�C/MINUTO. ESTE CRISTAL MAS ESTABLE, NO MOSTRARA UNA TRANSFORMACION DE ESTADO SOLIDO, INDEPENDIENTE DE LA FASE DE DISPERSION, EN LA PRODUCCION, ALMACENAMIENTO Y USO PARA EL TRATAMIENTO UNA ENFERMEDAD DE SOBRECARGA DE Fe o Al, MALARIA, ENTRE OTROSIT REFERS TO A PARENTERAL FORMULATION OF SUSTAINED RELEASE, WHICH INCLUDES: PARTICLES OF 5� TO 10� OF A DESPHERRIOXAMINE-B SALT OF AN ALIPHATIC SULPHONIC ACID OF AT LEAST 8 CARBONS, SUSPENDED IN OIL. IT ALSO REFERS TO A CRYSTALLINE FORM OF DESFERRIOXAMINE 1-DECANSULPHONATE OF FORMULA (I), CHARACTERIZED BY A MELTING POINT OF 154�CA 158�C, AND BY AN X-RAY DIFFACTION PATTERN IN 2U�: 3.1 4 , 2 7.3 8.4 9.4 10.5 13.7 16.8 17.4 18.0 18.4 19.6 20.1 20.9 22.3 23.7 25.1 25.6 . IT ALSO REFERS TO THE PREPARATION PROCEDURE OF SUCH CRYSTAL, WHICH INCLUDES: HEATING A DESPHERRIOXAMINE METHANOSULFONATE SOLUTION; ADD AN EQUIMOLAR AMOUNT OF A 1-DECANSULPHONIC ACID SALT; INDUCE CRYSTALLIZATION WITH A SEED CRYSTAL AND CONTINUE ADDING THE REST OF THE EQUIMOLAR AMOUNT OF SALT OF 1-DECANSULPHONIC ACID, OBTAINING A SATURATED SOLUTION IN HOT 1-DECANSULPHONATE OF ELEVADA, A SOLVENT SOLVENTE CRYSTALLIZATION OCCURS AT A COOLING SPEED OF 1�C / MINUTE. THIS MORE STABLE CRYSTAL WILL NOT SHOW A SOLID STATE TRANSFORMATION, REGARDLESS OF THE DISPERSION PHASE, IN THE PRODUCTION, STORAGE AND USE FOR THE TREATMENT OF AN OVERLOAD DISEASE OF FAITH OR AL, MALARIA, AMONG OTHERS

PE1997001097A 1996-12-10 1997-12-05 FORMULATIONS AND POLYMORPHIC FORMS OF DESPHERRIOXAMINE AND ITS PREPARATION PE27799A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH302496 1996-12-10
GBGB9625878.5A GB9625878D0 (en) 1996-12-12 1996-12-12 Compositions

Publications (1)

Publication Number Publication Date
PE27799A1 true PE27799A1 (en) 1999-03-18

Family

ID=25691970

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997001097A PE27799A1 (en) 1996-12-10 1997-12-05 FORMULATIONS AND POLYMORPHIC FORMS OF DESPHERRIOXAMINE AND ITS PREPARATION

Country Status (15)

Country Link
EP (1) EP0944586A2 (en)
KR (1) KR20000069376A (en)
CN (1) CN1239946A (en)
AR (1) AR009655A1 (en)
AU (1) AU5983998A (en)
BR (1) BR9713570A (en)
CA (1) CA2274761A1 (en)
CO (1) CO4910160A1 (en)
CZ (1) CZ204499A3 (en)
ID (1) ID22388A (en)
IL (1) IL130203A0 (en)
PE (1) PE27799A1 (en)
PL (1) PL334316A1 (en)
TR (1) TR199901260T2 (en)
WO (1) WO1998025887A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090016517A (en) * 1999-12-23 2009-02-13 벨루스 헬스 (인터내셔널) 리미티드 Compounds and methods for modulating cerebral amyloid angiopathy
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
DE10223913A1 (en) * 2002-05-29 2003-12-11 Bayer Cropscience Ag Process for the production of specific crystal modifications of polymorphic substances
NZ740675A (en) 2015-10-23 2024-02-23 Vifor Int Ag Novel ferroportin inhibitors
JOP20180036A1 (en) 2017-04-18 2019-01-30 Vifor Int Ag Novel ferroportin-inhibitor salts
TW202102478A (en) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 Novel iron chelators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH438351A (en) * 1959-09-25 1967-06-30 Ciba Geigy Process for the production of new growth substances
FR1898M (en) * 1961-04-07 1963-07-08 Ciba Geigy New substance usable in therapy.
GB9211779D0 (en) * 1992-06-03 1992-07-15 Ciba Geigy Ag Amine salts

Also Published As

Publication number Publication date
BR9713570A (en) 2000-03-14
ID22388A (en) 1999-10-07
EP0944586A2 (en) 1999-09-29
AU5983998A (en) 1998-07-03
AR009655A1 (en) 2000-04-26
WO1998025887A2 (en) 1998-06-18
TR199901260T2 (en) 1999-10-21
CA2274761A1 (en) 1998-06-18
WO1998025887A3 (en) 1998-08-13
CZ204499A3 (en) 1999-09-15
CN1239946A (en) 1999-12-29
CO4910160A1 (en) 2000-04-24
PL334316A1 (en) 2000-02-14
KR20000069376A (en) 2000-11-25
IL130203A0 (en) 2000-06-01

Similar Documents

Publication Publication Date Title
CO5271720A1 (en) PROCESS FOR MANUALLY MANUFACTURING HEMIPENTAHYDRATE AND MONOPENTAHYDRATE ACID 3-PIRIDIL-12HYDROXI-ETILIDEN-1, 1-BISFOPHOSNIC SODIUM AND PHARMACETIC COMPOSITION CONTAINING THEM
PE20020290A1 (en) FORMULA (I) EPOTILONE ANALOG POLYMORPHES
ECSP066645A (en) HERBED PYRIMIDINES
AR068527A2 (en) A PROCEDURE TO PREPARE CRYSTAL TIOTROPE BROMIDE MONOHIDRATE
HUP9903454A2 (en) A crystalline form of cefditoren pivoxyl and process for the production of the same
PE27799A1 (en) FORMULATIONS AND POLYMORPHIC FORMS OF DESPHERRIOXAMINE AND ITS PREPARATION
ES2090105T3 (en) PROCEDURE TO PURIFY AMINOMETHYLENE PHOSPHONIC ACIDS.
MX167804B (en) MICROPLASTIC STRUCTURES AND MANUFACTURING METHOD
PE20030629A1 (en) CRYSTALLINE SODIUM SALT AND PROCEDURE FOR ITS PREPARATION
AR229089A1 (en) PROCEDURE FOR THE PREPARATION OF ACID DERIVATIVES 2 - (MERCAPTOMETIL, -ETIL O-PROPIL) -1,3-DIOXO-1H-1,2,4-TRIAZOLO (1,2-A) PIRIDAZIN-5-CARBOXILICO
AR024222A1 (en) IMIDAZOLES WITH ANTI-INFLAMMATORY ACTIVITY A PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
AR008244A1 (en) HETERO CYCLICAL COMPOUNDS, PROCEDURE FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM, USE OF SUCH COMPOUNDS IN THE MANUFACTURE OF MEDICINES, AND USEFUL INTERMEDIARIES IN THE PREPARATION OF SUCH COMPOUNDS
PE20060170A1 (en) NEW CRYSTALLINE FORM OF 8-CYANE-1-CYCLOPROPYL-7- (1S, 6S-2,8-DIAZABICYCLO [4.3.0] NONAN-8-IL) -6-FLUORO-1,4-DIHYDRO-4-OXO ACID -3-QUINOLINE CARBOXYL
ES2079616T3 (en) CRYSTALLIZATION PROCEDURE IN THE PRESENCE OF A MAGNETIC FIELD.
CO4480032A1 (en) SPYROSTANYL GLYCOSID CRYSTALS
AR028968A1 (en) HETEROCICLIC DERIVATIVES OF AMINOALQUILPIRIDINA AS PSYCHOPHARMS
IE781277L (en) Benzoxaprofen
CA2470066A1 (en) 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
AR039733A1 (en) PROCESS FOR OBTAINING NORELGESTROMIN IN DIFFERENT RELATIONSHIPS OF ISOMEROS E AND Z
CO4970800A1 (en) THERMODYNAMICALLY STABLE FORM OF ACID (R) -3 ((((4-FLUORO- FENIL) SULFONIL) AMINO) -1,2,3,4-TETRAHIDRO-9H-CARBAZO-9-PRO-PANOICO (RAMATROBAN)
ES2139753T3 (en) THERMODYNAMICALLY STABLE CRYSTALLINE FORM OF THE SALT OF 4 '' BENZOIC ACID - DESOXI-4 '' - EPI-METHYLAMINE AVERMECTIN B1A / B1B AND PROCEDURE FOR ITS PREPARATION.
JPS5922986A (en) Heat-accumulating material
DK421183D0 (en) PROCEDURE FOR THE PREPARATION OF ALFA-ARYL-ALFA-PYRIDYLANIC ACIDS
JPS5425168A (en) Manufacture of heat sink for semiconductor
PE20030920A1 (en) CRYSTALLINE FORMS OF AGONISTS OF THE B3-ADRENERGIC RECEPTOR, PROCEDURE FOR THEIR PREPARATION AND THEIR USES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal